Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effect of finasteride on prostate-specific antigen density

G J Gormley1, J Ng, T Cook

  • 1Merck Research Laboratories, Rahway, New Jersey.

Urology
|January 1, 1994
PubMed
Summary

Finasteride treatment improved prostate-specific antigen density (PSAD) accuracy for prostate cancer detection. PSAD offers reassurance without needing PSA value adjustments during finasteride therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding the rationale for metronidazole use in dogs and cats.

The Journal of small animal practice·2025
Same author

Genetic therapies for movement disorders - current status.

Journal of neurology·2025
Same author

Behavioral, metabolic, and lipidomic characterization of the 5xFADxTg30 mouse model of Alzheimer's disease.

iScience·2024
Same author

Laboratory Study of Collisionless Magnetic Reconnection.

Space science reviews·2023
Same author

Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents.

Schizophrenia research·2023
Same author

Hybrid Simulations of the Cusp and Dayside Magnetosheath Dynamics Under Quasi-Radial Interplanetary Magnetic Fields.

Journal of geophysical research. Space physics·2023

Area of Science:

  • Urology
  • Oncology
  • Pharmacology

Background:

  • Prostate-specific antigen density (PSAD) is a key biomarker for prostate cancer diagnosis.
  • Finasteride's impact on PSAD may differ between benign prostatic hyperplasia (BPH) and prostate cancer.
  • Evaluating PSAD's diagnostic utility during finasteride treatment is crucial.

Purpose of the Study:

  • To assess the diagnostic performance of PSAD in men treated with finasteride for 12 months.
  • To determine if finasteride affects PSAD differently in men with BPH versus those with BPH and prostate cancer.
  • To evaluate the clinical utility of PSAD in the context of finasteride therapy.

Main Methods:

  • Analysis of data from 895 men with BPH in a 12-month placebo-controlled North American study.

Related Experiment Videos

  • Prostate volume measurement using magnetic resonance imaging (MRI).
  • Prostate-specific antigen (PSA) measurement via the Hybritech immunoradiometric assay.

    • Main Results:

    • Finasteride treatment for 12 months increased the positive predictive value (PPV) of PSAD for prostate cancer from 14% to 30%.
    • Using adjusted PSA cutoffs (10 ng/mL at baseline, 5 ng/mL after 12 months) achieved similar specificity and sensitivity.
    • PSAD provided diagnostic value without requiring PSA value adjustments.

    Conclusions:

    • Adjusting PSA values during finasteride treatment can maintain diagnostic accuracy for prostate cancer.
    • PSAD can offer additional reassurance for prostate cancer diagnosis without requiring treatment-specific adjustments.
    • These findings support the use of PSAD as a valuable tool in managing patients on finasteride therapy.